Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Berk

Showing results (361-370 of 398) with videos related to

Pageof 40
Sort By:
Stem Cell Reports|November 29, 2013
Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosisAmy Leung, Shirley K Nah, Whitney Reid, et al.
Journal of the Peripheral Nervous System : JPNS|November 8, 2022
Liver-directed drugs for transthyretin-mediated amyloidosisThomas H Brannagan, John L Berk, Julian D Gillmore, et al.
Health Services Research|December 11, 1999
National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization studyM F Shapiro, M L Berk, S H Berry, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 25, 2022
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trialDavid Adams, Ivailo L Tournev, Mark S Taylor, et al.
American Journal of Hematology|June 22, 2022
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal studyJoshua N Gustine, Andrew Staron, Raphael E Szalat, et al.
Journal of Cardiac Failure|December 8, 2023
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin AmyloidosisAhmad Masri, Mathew S Maurer, Brian L Claggett, et al.
Journal of the American College of Cardiology|August 6, 2025
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-BMathew S Maurer, John L Berk, Thibaud Damy, et al.
Journal of Neurology|August 14, 2024
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 9, 2026
Guidelines for the management of hereditary ATTR amyloidosis 2026Yoshiki Sekijima, Mitsuharu Ueda, John L Berk, et al.
Journal of Neurology|February 3, 2025
Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Pageof 40

Showing results (361-370 of 398) with videos related to

Sort By:
Pageof 40
Stem Cell Reports|November 29, 2013
Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosisAmy Leung, Shirley K Nah, Whitney Reid, et al.
Journal of the Peripheral Nervous System : JPNS|November 8, 2022
Liver-directed drugs for transthyretin-mediated amyloidosisThomas H Brannagan, John L Berk, Julian D Gillmore, et al.
Health Services Research|December 11, 1999
National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization studyM F Shapiro, M L Berk, S H Berry, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 25, 2022
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trialDavid Adams, Ivailo L Tournev, Mark S Taylor, et al.
American Journal of Hematology|June 22, 2022
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal studyJoshua N Gustine, Andrew Staron, Raphael E Szalat, et al.
Journal of Cardiac Failure|December 8, 2023
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin AmyloidosisAhmad Masri, Mathew S Maurer, Brian L Claggett, et al.
Journal of the American College of Cardiology|August 6, 2025
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-BMathew S Maurer, John L Berk, Thibaud Damy, et al.
Journal of Neurology|August 14, 2024
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 9, 2026
Guidelines for the management of hereditary ATTR amyloidosis 2026Yoshiki Sekijima, Mitsuharu Ueda, John L Berk, et al.
Journal of Neurology|February 3, 2025
Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformIsabel Conceição, John L Berk, Markus Weiler, et al.
Pageof 40